The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
Abstract
The "catecholamine hypothesis of affective disorders" proposes that some, if not all, depressions are associated with an absolute or relative decrease in catecholamines, particularly norepinephrine, available at central adrenergic receptor sites. Elation, conversely, may be associated with an excess of such amines. Evidence supporting this hypothesis was reviewed. Data from pharmacological studies, mainly in animals, suggest that the actions of both major classes of antidepressant drugs are mediated through the catecholamines. The monoamine oxidase inhibitors increase brain concentrations of norepinephrine while imipramine-like agents potentiate the physiological effects of norepinephrine. Reserpine, a drug which can cause clinical depression, depletes catecholamines, but other amines may also be involved in its mechanism of action. A rigorous extrapolation from pharmacological studies to pathophysiology clearly cannot be made. Clinical studies relevant to the catecholamime hypothesis are limited and the findings are inconclusive. It is not possible, therefore, to confirm definitively or to reject the catecholamine hypothesis on the basis of data currently available. In our present state of knowledge, however, the catecholamine hypothesis is of considerable heuristic value, providing the investigator and the clinician with a frame of reference integrating much of our experience with those pharmacological agents which produce alterations in human affective states.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,278
A CONCEPT FOR A ROLE OF SEROTONIN AND NOREPINEPHRINE AS CHEMICAL MEDIATORS IN THE BRAIN
Brodie, B. B., & Shore, P. A. (1957) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1957.tb40753.x · Cited by 637
POTENTIATION OF THE ANTIDEPRESSIVE EFFECT OF A MONOAMINE-OXIDASE INHIBITOR BY TRYPTOPHAN
Coppen, A., Shaw, D., & Farrell, J. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91084-5 · Cited by 344
Marley, E. (1962) · Psychopharmacologia · doi:10.1007/bf00411372 · Cited by 218
MODIFICATIONS OF THE PHARMACOLOGY OF RESERPINE AND SEROTONIN BY IPRONIAZID
Chessin, M., Kramer, E. R., & Scott, C. C. (1957) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11898-3 · Cited by 112
Achor, R. W. P. (1955) · JAMA · doi:10.1001/jama.1955.02960260011004 · Cited by 91
Potentiation of the behavioral effects of amphetamine by imipramine
Carlton, P. L. (1961) · Psychopharmacology · doi:10.1007/bf00404124 · Cited by 87
BUSFIELD, B. L., WECHSLER, H., & BARNUM, W. J. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710170050006 · Cited by 27
Research works printed but not linked: 10
- 10.1007/978-1-4684-8306-2_14 · doi:10.1007/978-1-4684-8306-2_14
- Axelrod J., 1963, : The Clinical Chemistry of Monoamines.
- 10.1016/S0079-6123(08)60119-3 · doi:10.1016/s0079-6123(08)60119-3
- Bergsman A., 1959, Acta Psychiat. Neurol. Scand. 33:suppl. 133
- Carlsson A., 1961, Neuropsychopharmacology, 2, 417
- 10.1016/S0079-6123(08)60110-7 · doi:10.1016/s0079-6123(08)60110-7
- Carlsson A., 1960, : Adrenergic Mechanisms.
- 10.1007/978-1-4684-8306-2_16 · doi:10.1007/978-1-4684-8306-2_16
- Cole, 1961, J. 0., Jones, R. T., and Kierman, C. L.: Drug Therapy, Progr. Neurol. Psychiat., 16, 539
- Cole, 1960, J. 0., Klerman, G. L., and Jones, R. T.: Drug Therapy, Progr. Neurol. Psychiat., 15, 540
Cited by
Items 101–200 of 251
Bymaster, F. P., Zhang, W., Carter, P. A., Shaw, J., Chernet, E., Phebus, L., Wong, D. T., & Perry, K. W. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0986-x · Cited by 334
Gardner, A., & Boles, R. G. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.030 · Cited by 333
“A causal relationship was suggested between disturbances in monoamine metabolism and depression (Coppen, 1967; Schildkraut, 1965).”
BackgroundThe psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans
Wichers, M., & Maes, M. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003103 · Cited by 329
Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328
“For example, hypotheses have been proposed regarding the involvement of serotonin and norepinephrine in mood disorders (Schildkraut, 1965; Glowinski and Axelrod, 1965; Coppen, 1967; Bunney and Davis, 1965; Coppen and Doogan, 1988; Caldecott-Hazard et al, 1991; Markou et al, 1998), dopamine dysfunction in schizophrenia…”
Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease
Weinshenker, D. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.01.010 · Cited by 323
Presynaptic Alpha-Receptor Subsensitivity After Long-Term Antidepressant Treatment
Crews, F. T., & Smith, C. B. (1978) · Science · doi:10.1126/science.211589 · Cited by 322
Effects of antidepressant drugs on different receptors in the brain
Hall, H., & Sven-Ove, Ö. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90172-2 · Cited by 320
Serotonergic modulation of the limbic system
Hensler, J. G. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.06.007 · Cited by 319
Applications for α-lactalbumin in human nutrition
Layman, D. K., Lönnerdal, B., & Fernstrom, J. D. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy004 · Cited by 316
Trace amine-associated receptors and their ligands
Zucchi, R., Chiellini, G., Scanlan, T. S., & Grandy, D. K. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706948 · Cited by 314
Koslow, S. H. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790080081011 · Cited by 312
Role of norepinephrine in the pathophysiology and treatment of mood disorders
Ressler, K. J., & Nemeroff, C. B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00127-4 · Cited by 307
Delgado, P. L., Miller, H. L., Salomon, R. M., Licinio, J., Krystal, J. H., Moreno, F. A., Heninger, G. R., & Charney, D. S. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00014-1 · Cited by 307
Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders
Müller, N., & Ackenheil, M. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(97)00179-6 · Cited by 306
Abnormalities of Indoleamines in Affective Disorders
Coppen, A. (1972) · Archives of General Psychiatry · doi:10.1001/archpsyc.1972.01750230084016 · Cited by 304
Lambert, G., Johansson, M., Ågren, H., & Friberg, P. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.787 · Cited by 303
MAOIs in the Contemporary Treatment of Depression
Thase, M. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00058-8 · Cited by 301
Influence of aerobic exercise on depression
McCann, I. L., & Holmes, D. S. (1984) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.46.5.1142 · Cited by 297
The many faces of fatigue in major depressive disorder
Demyttenaere, K., De Fruyt, J., & Stahl, S. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004729 · Cited by 288
“Schildkraut JJ (1965). The catecholamine hypothesis of”
BackgroundSrinivasan, V., Smits, M., Spence, W., Lowe, A. D., Kayumov, L., Pandi-Perumal, S. R., Parry, B., & Cardinali, D. P. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970600571822 · Cited by 292
Starkman, M. N., Schteingart, D. E., & Schork, A. M. (1981) · Psychosomatic Medicine · doi:10.1097/00006842-198102000-00002 · Cited by 289
Bernaras, E., Jaureguizar, J., & Garaigordobil, M. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.00543 · Cited by 288
Relation of Sex and Aging to Monoamine Oxidase Activity of Human Brain, Plasma, and Platelets
Robinson, D. S. (1971) · Archives of General Psychiatry · doi:10.1001/archpsyc.1971.01750120052009 · Cited by 287
Pathophysiology of depression and mechanisms of treatment
Brigitta, B. (2002) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2002.4.1/bbondy · Cited by 286
Sex steroids and affect in the surgical menopause: a double-blind, cross-over study
Sherwin, B. (1985) · Psychoneuroendocrinology · doi:10.1016/0306-4530(85)90009-5 · Cited by 285
An excitatory synapse hypothesis of depression
Thompson, S. M., Kallarackal, A. J., Kvarta, M. D., Van Dyke, A. M., LeGates, T. A., & Cai, X. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.03.003 · Cited by 265
Andrews, P. W., Bharwani, A., Lee, K. R., Fox, M., & Thomson, J. A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.018 · Cited by 281
“The monoamine-enhancing effect of antidepressant medications (ADMs), coupled with the depressioninducing effects of reserpine, suggested that depression was caused by reduced monoamine neurotransmission (Everett and Toman, 1959; Jacobsen, 1964; Schildkraut, 1965).”
BackgroundMicroglia in depression: current perspectives
Jia, X., Gao, Z., & Hu, H. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1815-6 · Cited by 282
Neurobiological effects of exercise on major depressive disorder: A systematic review
Schuch, F. B., Deslandes, A. C., Stubbs, B., Gosmann, N. P., Silva, C. T. B. D., & Fleck, M. P. D. A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.11.012 · Cited by 279
Nicotinic acetylcholine receptors as targets for antidepressants
Shytle, R. D., Silver, A. A., Lukas, R. J., Newman, M. B., Sheehan, D. V., & Sanberg, P. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001035 · Cited by 279
Frontal lobe dysfunction in secondary depression
(1994) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.6.4.428 · Cited by 276
L-Tryptophan in Mania: Contribution to a Permissive Hypothesis of Affective Disorders
Prange, A. J. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760070040006 · Cited by 274
Dopamine and depression: A review of recent evidence. I. Empirical studies
Willner, P. (1983) · Brain Research Reviews · doi:10.1016/0165-0173(83)90005-x · Cited by 273
Maes, M., Vandoolaeghe, E., Neels, H., Demedts, P., Wauters, A., Meltzer, H. Y., Altamura, C., & Desnyder, R. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00365-4 · Cited by 272
Rogers, R. D., Tunbridge, E. M., Bhagwagar, Z., Drevets, W. C., Sahakian, B. J., & Carter, C. S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300001 · Cited by 270
Pharmacology of Antidepressants
Frazer, A. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199704001-00002 · Cited by 269
Parental Depression: Animal Models of an Adverse Life Event
Newport, D. J., Stowe, Z. N., & Nemeroff, C. B. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1265 · Cited by 266
Cortisol and major depressive disorder-translating findings from humans to animal models and Back
Nandam, L. S., Brazel, M., Zhou, M., & Jhaveri, D. J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00974 · Cited by 265
Parachlorophenylalanine Reversal of Tranylcypromine Effects in Depressed Patients
Shopsin, B. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770070041003 · Cited by 265
Depressive Symptomatology and Incident Cognitive Decline in an Elderly Community Sample
Bassuk, S. S., Berkman, L. F., & Wypij, D. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1073 · Cited by 263
Psychomotor Activity and Cerebrospinal Fluid Amine Metabolites in Affective Illness
POST, R. M., KOTIN, J., GOODWIN, F. K., & GORDON, E. K. (1973) · American Journal of Psychiatry · doi:10.1176/ajp.130.1.67 · Cited by 262
Hammer, W., & Sjöqvist, F. (1967) · Life Sciences · doi:10.1016/0024-3205(67)90218-4 · Cited by 262
Karimi-Maleh, H., Sheikhshoaie, M., Sheikhshoaie, I., Ranjbar, M., Alizadeh, J., Maxakato, N. W., & Abbaspourrad, A. (2019) · New Journal of Chemistry · doi:10.1039/c8nj05581e · Cited by 261
Grønli, J., Bramham, C., Murison, R., Kanhema, T., Fiske, E., Bjorvatn, B., Ursin, R., & Portas, C. M. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.11.021 · Cited by 260
Mood changes in stroke patients: Relationship to lesion location
Robinson, R. G., Kubos, K. L., Starr, L. B., Rao, K., & Price, T. R. (1983) · Comprehensive Psychiatry · doi:10.1016/0010-440x(83)90024-x · Cited by 258
Di Chiara, G., Loddo, P., & Tanda, G. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00236-x · Cited by 258
Affective changes with estrogen and androgen replacement theraphy in surgically menopausal women
Sherwin, B. B. (1988) · Journal of Affective Disorders · doi:10.1016/0165-0327(88)90061-4 · Cited by 258
A review of the role of serotonin receptors in psychiatric disorders
Naughton, M., Mulrooney, J. B., & Leonard, B. E. (2000) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/1099-1077(200008)15:6<397::aid-hup212>3.0.co;2-l · Cited by 258
Regular Induction of Hypomania by L-Dopa in “Bipolar” Manic-depressive Patients
MURPHY, D. L., BRODIE, H. K. H., GOODWIN, F. K., & BUNNEY, W. E. (1971) · Nature · doi:10.1038/229135a0 · Cited by 257
Brain histamine receptors as targets for antidepressant drugs
Kanof, P. D., & Greengard, P. (1978) · Nature · doi:10.1038/272329a0 · Cited by 257
Kramer, M. S., Winokur, A., Kelsey, J., Preskorn, S. H., Rothschild, A. J., Snavely, D., Ghosh, K., Ball, W. A., Reines, S. A., Munjack, D., et al. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300260 · Cited by 256
Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity
Stuart, M. J., & Baune, B. T. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.10.001 · Cited by 257
Elevated plasma nitrate levels in depressive states
Suzuki, E., Yagi, G., Nakaki, T., Kanba, S., & Asai, M. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00164-6 · Cited by 255
Serotonin: A never-ending story
Olivier, B. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.031 · Cited by 253
Effect of experimental cerebral infarction in rat brain on catecholamines and behaviour
ROBINSON, R. G., SHOEMAKER, W. J., SCHLUMPF, M., VALK, T., & BLOOM, F. E. (1975) · Nature · doi:10.1038/255332a0 · Cited by 252
Morilak, D. A., & Frazer, A. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004080 · Cited by 252
Monoamine oxidase and cigarette smoking
Fowler, J. S., Logan, J., Wang, G.-J., & Volkow, N. D. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(02)00109-2 · Cited by 251
“This revelation, in part, contributed to the hypothesis that monoamine regulation may be related to mood and led to the development and application of MAO inhibitor drugs in the treatment of depression (Schildkraut, 1965).”
BackgroundFrom Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder
Liu, B., Liu, J., Wang, M., Zhang, Y., & Li, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00305 · Cited by 249
Pinna, G., Costa, E., & Guidotti, A. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0213-2 · Cited by 245
Tremblay, L. K., Naranjo, C. A., Cardenas, L., Herrmann, N., & Busto, U. E. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.409 · Cited by 229
Réus, G. Z., Jansen, K., Titus, S., Carvalho, A. F., Gabbay, V., & Quevedo, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.05.007 · Cited by 221
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
Vagal nerve stimulation for treatment-resistant depression
Carreno, F. R., & Frazer, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0537-8 · Cited by 208
Panksepp, J., & Watt, D. (2011) · Psychiatry: Interpersonal and Biological Processes · doi:10.1521/psyc.2011.74.1.5 · Cited by 207
Miller, H. L. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020031005 · Cited by 192
Neuronal network plasticity and recovery from depression
Castrén, E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1 · Cited by 190
Papakostas, G. I., Shelton, R. C., Kinrys, G., Henry, M. E., Bakow, B. R., Lipkin, S. H., Pi, B., Thurmond, L., & Bilello, J. A. (2013) · Molecular Psychiatry · doi:10.1038/mp.2011.166 · Cited by 180
Kemp, A. H., Gordon, E., Rush, A. J., & Williams, L. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900017120 · Cited by 170
Antidepressant-like effect of harmane and other β-carbolines in the mouse forced swim test
Farzin, D., & Mansouri, N. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.08.005 · Cited by 171
“According to this hypothesis, a functional decrease in the activity of brain amines, particularly norepinephrine, dopamine and 5-HTwould result in depression (Prange, 1964; Schildkraut, 1965; Randrup and Braestrup, 1977; Maes and Meltzer, 1995; Schatzberg and Schildkraut, 1995).”
BackgroundPost, R. M. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770290091008 · Cited by 168
Assessment and treatment of depression in the cancer patient
Newport, D. J., & Nemeroff, C. B. (1998) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(98)00011-7 · Cited by 167
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
Xu, H., Steven Richardson, J., & Li, X.-M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300009 · Cited by 167
“The initial hypothesis for the action of antidepressants (the so-called monoamine hypothesis: Bunney and Davis, 1965; Schildkraut, 1965) was based mainly on the elevation of brain levels of noradrenaline and serotonin produced by the early tricyclic and monoamine oxidase inhibitor antidepressants.”
BackgroundNeuropathology of suicide: Recent findings and future directions
Lutz, P.-E., Mechawar, N., & Turecki, G. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.141 · Cited by 158
Cytokines as biomarkers in depressive disorder: current standing and prospects
Lichtblau, N., Schmidt, F. M., Schumann, R., Kirkby, K. C., & Himmerich, H. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.813442 · Cited by 155
Mitochondrial dysfunction, oxidative stress, and major depressive disorder
Tobe, E. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s44282 · Cited by 156
Küçükibrahimoğlu, E., Saygın, M. Z., Çalışkan, M., Kaplan, O. K., Ünsal, C., & Gören, M. Z. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0650-7 · Cited by 155
Microglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 154
Clinical and Neurobiological Effects of Tianeptine and Paroxetine in Major Depression
Nickel, T., Sonntag, A., Schill, J., Zobel, A. W., Ackl, N., Brunnauer, A., Murck, H., Ising, M., Yassouridis, A., Steiger, A., et al. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00008 · Cited by 152
GABAergic Control of Depression-Related Brain States
Luscher, B., & Fuchs, T. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2014.11.003 · Cited by 149
“Conversely, the monoaminergic deficit hypothesis of MDD posits that defects in these mechanisms underlie depressive states (Bunney & Davis, 1965; Coppen, 1967; Matussek, 1969; J. Schildkraut, 1965).”
BackgroundNrf2 participates in depressive disorders through an anti-inflammatory mechanism
Martín-de-Saavedra, M. D., Budni, J., Cunha, M. P., Gómez-Rangel, V., Lorrio, S., del Barrio, L., Lastres-Becker, I., Parada, E., Tordera, R. M., Rodrigues, A. L. S., et al. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.03.020 · Cited by 143
The importance of n-6/n-3 fatty acids ratio in the major depressive disorder
Husted, K. S., & Bouzinova, E. V. (2016) · Medicina · doi:10.1016/j.medici.2016.05.003 · Cited by 142
Role of the intestinal microbiome, intestinal barrier and psychobiotics in depression
Trzeciak, P., & Herbet, M. (2021) · Nutrients · doi:10.3390/nu13030927 · Cited by 139
Neuropeptide and small transmitter coexistence: Fundamental studies and relevance to mental illness
Hökfelt, T., Barde, S., Xu, Z.-Q. D., Kuteeva, E., Rüegg, J., Le Maitre, E., Risling, M., Kehr, J., Ihnatko, R., Theodorsson, E., et al. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00106 · Cited by 139
Dhir, A., & Kulkarni, S. K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.04.028 · Cited by 133
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
P2X7 Receptor Signaling in Stress and Depression
Ribeiro, D. E., Roncalho, A. L., Glaser, T., Ulrich, H., Wegener, G., & Joca, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112778 · Cited by 129
“Evidence from recent decades has revealed that the neur biology of depression is significa l more complex han initially proposed when the ‘catecholamine hyp thes s of depression’ was proposed [16].”
BackgroundChen, M. J., & Russo‐Neustadt, A. A. (2009) · Hippocampus · doi:10.1002/hipo.20579 · Cited by 129
Altered Waveform of Plasma Nocturnal Melatonin Secretion in Premenstrual Depression
Parry, B. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240059010 · Cited by 128
The effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression
McLean, A., Rubinsztein, J. S., Robbins, T. W., & Sahakian, B. J. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1586-8 · Cited by 125
“Originating with the catecholamine (Schildkraut 1965) and indoleamine (Lapin and Oxenkrug 1969) hypotheses of depression, investigations into the biochemical basis of depression have largely focused on the roles of serotonin (5-HT) and noradrenaline (NA).”
BackgroundBraslow, J. T., & Marder, S. R. (2019) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050718-095514 · Cited by 122
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients
Ferguson, J. M., Wesnes, K. A., & Schwartz, G. E. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200301000-00002 · Cited by 112
“There has been speculation in the medical research literature for over 30 years about the role of catecholamines in cognition and depression (Schildkraut, 1965; Crow, 1968; Mason and Iverson, 1977; Friedman et al., 1999; Ressler and Nemeroff, 1999).”
Zellner, M. R., Watt, D. F., Solms, M., & Panksepp, J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.01.003 · Cited by 112
24-h Monitoring of plasma norepinephrine, MHPG, cortisol, growth hormone and prolactin in depression
Koenigsberg, H. W., Teicher, M. H., Mitropoulou, V., Navalta, C., New, A. S., Trestman, R., & Siever, L. J. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.03.006 · Cited by 104
Kambeitz, J. P., & Howes, O. D. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.07.034 · Cited by 96
Sarter, M., Bruno, J. P., & Parikh, V. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301285 · Cited by 100
From synapse to nucleus: Novel targets for treating depression
Covington, H. E., Vialou, V., & Nestler, E. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.004 · Cited by 98
Antidepressants in inflammatory bowel disease
Mikocka-Walus, A., Ford, A. C., & Drossman, D. A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0259-y · Cited by 93
Metadata
- Authors
- SCHILDKRAUT, J. J.
- Venue
- American Journal of Psychiatry
- Published
- 1965-11
- Volume
- 122
- Issue
- 5
- Pages
- 509-522
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2072219714
- Cited by
- 3,492
- References
- 8
- FWCI
- 39.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.